Ingmar Mederacke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ingmar Mederacke has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
Michael P. Manns
Hannover Med Sch, Gastroenterol Hepatol & Endocrinol, Hannover, Germany
7 shared publicationsHeiner Wedemeyer
5 shared publicationsYoung-Seon Mederacke
5 shared publicationsFlorian Hamberger
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
3 shared publications- Heiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
3 shared publications Regina Raupach
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany
3 shared publications
Latest Publications
- Open Access
- 28 March 2025
- Published by S. Karger AG in Digestive Diseases
- Vol. 43 (4) , 423-433
LKM Immunofluorescence Is Associated with DILI, Especially after Metamizole Intake
Introduction: Drug-induced liver injury (DILI) is a rare but potentially serious clinical condition. One phenotype of DILI is termed drug-induced autoimmune like hepatitis (DI-ALH) that presents with laboratory and histological features indistinguishable from autoimmune hepatitis. Liver kidney microsomal antibodies (LKM-antibodies) are common in the diagnosis of AIH but were also described to be associated with halothane-induced DILI. Also, the antigens of anti-LKM-1 and anti-LKM-2 belong to the cytochrome P450 enzyme family that is involved in the metabolism of various drugs. Therefore, we aimed to study the impact of LKM-antibodies in the diagnostic work-up of suspected DILI in a large cohort of patients with liver injury in a tertiary care centre. Methods: We screened a large single centre hospital database and retrospectively identified 63,300 cases with liver injury as defined: AST or ALT >3 upper limit of normal (ULN) or AP or TBI >2 ULN. Of those, 82 cases with LKM immunofluorescence positivity (titre ≥1: 160) were identified, of which 64 patients fulfilled the inclusion criteria for this study. Results: Positive LKM immunofluorescence was associated with drug-induced autoimmune-like hepatitis (DI-ALH). Metamizole association was identified in half of the patients (n = 33, 52%). Eight patients with metamizole associated DI-ALHs required liver transplantation and 1 patient died. Conclusion: DI-ALH, especially after metamizole administration, can be a reason for a positivity in LKM immunofluorescence tests. Metamizole DI-ALH has a high liver-related mortality.
- 28 March 2025
- Published by S. Karger AG in Digestive Diseases
- Vol. 43 (4) , 423-433
Open AccessLKM Immunofluorescence Is Associated with DILI, Especially after Metamizole Intake
Introduction: Drug-induced liver injury (DILI) is a rare but potentially serious clinical condition. One phenotype of DILI is termed drug-induced autoimmune like hepatitis (DI-ALH) that presents with laboratory and histological features indistinguishable from autoimmune hepatitis. Liver kidney microsomal antibodies (LKM-antibodies) are common in the diagnosis of AIH but were also described to be associated with halothane-induced DILI. Also, the antigens of anti-LKM-1 and anti-LKM-2 belong to the cytochrome P450 enzyme family that is involved in the metabolism of various drugs. Therefore, we aimed to study the impact of LKM-antibodies in the diagnostic work-up of suspected DILI in a large cohort of patients with liver injury in a tertiary care centre. Methods: We screened a large single centre hospital database and retrospectively identified 63,300 cases with liver injury as defined: AST or ALT >3 upper limit of normal (ULN) or AP or TBI >2 ULN. Of those, 82 cases with LKM immunofluorescence positivity (titre ≥1: 160) were identified, of which 64 patients fulfilled the inclusion criteria for this study. Results: Positive LKM immunofluorescence was associated with drug-induced autoimmune-like hepatitis (DI-ALH). Metamizole association was identified in half of the patients (n = 33, 52%). Eight patients with metamizole associated DI-ALHs required liver transplantation and 1 patient died. Conclusion: DI-ALH, especially after metamizole administration, can be a reason for a positivity in LKM immunofluorescence tests. Metamizole DI-ALH has a high liver-related mortality.
- 10 January 2024
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 62 (06) , 919-929
Elevated liver enzymes in a German tertiary-care hospital: Distribution, diagnostic steps and diagnosis groups
Background The determination of liver blood tests is frequently performed in hospitalized patients, and abnormal values require further diagnostics. Yet, analyses considering the management of elevated liver enzymes are missing. Therefore, this study aimed to analyze the distribution of abnormal liver function tests and the subsequent diagnostic steps across different medical specialties. Methods From our Hannover liver-injury database, we identified 63,300 cases of patients who were hospitalized between January 2008 and July 2021 with AST or ALT > 3 ULN or AP or TBI > 2 ULN at any time point during hospitalization. Of these, 29,547 cases fulfilled the inclusion criteria and were subjected to further analysis. Cases were analyzed according to the three groups: internal medicine, surgery and others. Analyses were performed regarding baseline characteristics, liver-related diagnostics and factors influencing hospital mortality. Results Elevated liver blood tests were mainly observed in internal medicine (n=17,762, 60.1%), followed by the surgery department 34.2% (n=10,105). Notably, 40.2% (n=11,896) developed liver enzyme elevation above the cut-offs during the hospital stay. Testing for hepatitis B and C was more often performed in the surgery department compared to in internal medicine. In total, 5.6% of the cases (n=1,640) had a liver biopsy. Hyperbilirubinemia (total bilirubine ≥ 2ULN) and AST/ALT ratios >2 were associated with in-hospital mortality. Conclusion Clinicians are often faced with elevated liver enzymes. However, diagnostic steps differ between different specialties. Physicians should be aware of the increased in-hospital mortality in cases with hyperbilirubinemia or elevated AST/ALT ratios.
- 10 January 2024
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 62 (06) , 919-929
Elevated liver enzymes in a German tertiary-care hospital: Distribution, diagnostic steps and diagnosis groups
Background The determination of liver blood tests is frequently performed in hospitalized patients, and abnormal values require further diagnostics. Yet, analyses considering the management of elevated liver enzymes are missing. Therefore, this study aimed to analyze the distribution of abnormal liver function tests and the subsequent diagnostic steps across different medical specialties. Methods From our Hannover liver-injury database, we identified 63,300 cases of patients who were hospitalized between January 2008 and July 2021 with AST or ALT > 3 ULN or AP or TBI > 2 ULN at any time point during hospitalization. Of these, 29,547 cases fulfilled the inclusion criteria and were subjected to further analysis. Cases were analyzed according to the three groups: internal medicine, surgery and others. Analyses were performed regarding baseline characteristics, liver-related diagnostics and factors influencing hospital mortality. Results Elevated liver blood tests were mainly observed in internal medicine (n=17,762, 60.1%), followed by the surgery department 34.2% (n=10,105). Notably, 40.2% (n=11,896) developed liver enzyme elevation above the cut-offs during the hospital stay. Testing for hepatitis B and C was more often performed in the surgery department compared to in internal medicine. In total, 5.6% of the cases (n=1,640) had a liver biopsy. Hyperbilirubinemia (total bilirubine ≥ 2ULN) and AST/ALT ratios >2 were associated with in-hospital mortality. Conclusion Clinicians are often faced with elevated liver enzymes. However, diagnostic steps differ between different specialties. Physicians should be aware of the increased in-hospital mortality in cases with hyperbilirubinemia or elevated AST/ALT ratios.
- Open Access
- 5 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-7
An inducible model for genetic manipulation and fate-tracing of PDGFRβ-expressing fibrogenic cells in the liver
Myofibroblasts are the source of extracellular matrix protein during liver fibrogenesis. Fibroblasts, hepatic stellate cells (HSCs) and vascular smooth muscle cells are mesenchymal subpopulations in the liver that are characterized by the expression of PDGFRβ and contribute to the pool of these myofibroblasts. Conditional knockout models are important to better understand the function of specific liver cell populations including mesenchymal cells. While there is a limited number of constitutive mouse models for liver mesenchymal cell specific transgene expression, there is no established model for inducible gene targeting in HSCs or PDGFRβ-expressing mesenchymal cell populations in the liver. To address this, we investigated whether the tamoxifen inducible PDGFRβ-P2A-CreERT2 mouse can be used as a reliable tool to specifically express transgens in liver mesenchymal cells. Our data demonstrate, that PDGFRβ-P2A-CreERT2 specifically and efficiently marks over 90% of retinoid positive HSCs in healthy and fibrotic liver in mice upon tamoxifen injection, and that those cells give rise to Col1a1-expressing myofibroblasts in different models of liver fibrosis. Together with a negligible background recombination of only about 0.33%, this confirms that the PDGFRβ-P2A-CreERT2 mouse is nearly as efficient as established constitutive LratCre and PDGFRβ-Cre mouse models for recombination in HSCs, and that it is a powerful model for mesenchymal liver cell studies that require an inducible Cre approach.
- 5 May 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-7
Open AccessAn inducible model for genetic manipulation and fate-tracing of PDGFRβ-expressing fibrogenic cells in the liver
Myofibroblasts are the source of extracellular matrix protein during liver fibrogenesis. Fibroblasts, hepatic stellate cells (HSCs) and vascular smooth muscle cells are mesenchymal subpopulations in the liver that are characterized by the expression of PDGFRβ and contribute to the pool of these myofibroblasts. Conditional knockout models are important to better understand the function of specific liver cell populations including mesenchymal cells. While there is a limited number of constitutive mouse models for liver mesenchymal cell specific transgene expression, there is no established model for inducible gene targeting in HSCs or PDGFRβ-expressing mesenchymal cell populations in the liver. To address this, we investigated whether the tamoxifen inducible PDGFRβ-P2A-CreERT2 mouse can be used as a reliable tool to specifically express transgens in liver mesenchymal cells. Our data demonstrate, that PDGFRβ-P2A-CreERT2 specifically and efficiently marks over 90% of retinoid positive HSCs in healthy and fibrotic liver in mice upon tamoxifen injection, and that those cells give rise to Col1a1-expressing myofibroblasts in different models of liver fibrosis. Together with a negligible background recombination of only about 0.33%, this confirms that the PDGFRβ-P2A-CreERT2 mouse is nearly as efficient as established constitutive LratCre and PDGFRβ-Cre mouse models for recombination in HSCs, and that it is a powerful model for mesenchymal liver cell studies that require an inducible Cre approach.
- Open Access
- 15 February 2023
- Published by F1000 Research Ltd in F1000Research
- Vol. 12, 178
Autoimmune hepatitis in young Somalian men – experience from a German tertiary care center
Background: Autoimmune hepatitis (AIH) is a rare liver disease predominantly affecting women. Data on AIH in African patients is rare. A previous study from the UK reported an unusual form of AIH in Somalian patients. Methods: To examine whether this form of AIH can also be found in Germany, we screened the database of a major tertiary liver transplantation center. Results and conclusions: Among 17 Somalian patients presenting to our hospital between 2008 and 2021 three male patients were admitted with liver disease. All three of them were diagnosed with AIH. Here, we present the clinical courses highlighting diagnostic challenges and the particular severity of liver disease. These cases emphasize the need to consider AIH as an important differential diagnosis in Somalian patients presenting with new onset of hepatopathy.
- 15 February 2023
- Published by F1000 Research Ltd in F1000Research
- Vol. 12, 178
Open AccessAutoimmune hepatitis in young Somalian men – experience from a German tertiary care center
Background: Autoimmune hepatitis (AIH) is a rare liver disease predominantly affecting women. Data on AIH in African patients is rare. A previous study from the UK reported an unusual form of AIH in Somalian patients. Methods: To examine whether this form of AIH can also be found in Germany, we screened the database of a major tertiary liver transplantation center. Results and conclusions: Among 17 Somalian patients presenting to our hospital between 2008 and 2021 three male patients were admitted with liver disease. All three of them were diagnosed with AIH. Here, we present the clinical courses highlighting diagnostic challenges and the particular severity of liver disease. These cases emphasize the need to consider AIH as an important differential diagnosis in Somalian patients presenting with new onset of hepatopathy.
- 6 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (639) , eabe5795
The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver
Fibrosis contributes to ~45% of deaths in western countries. In chronic liver disease, fibrosis is a major factor determining outcomes, but efficient antifibrotic therapies are lacking. Although platelet-derived growth factor and transforming growth factor–β constitute key fibrogenic mediators, they do not account for the well-established link between cell death and fibrosis in the liver. Here, we hypothesized that damage-associated molecular patterns (DAMPs) may link epithelial cell death to fibrogenesis in the injured liver. DAMP receptor screening identified purinergic receptor P2Y14 among several candidates as highly enriched in hepatic stellate cells (HSCs), the main fibrogenic cell type of the liver. Conversely, P2Y14 ligands uridine 5′-diphosphate (UDP)–glucose and UDP-galactose were enriched in hepatocytes and were released upon different modes of cell death. Accordingly, ligand-receptor interaction analysis that combined proteomic and single-cell RNA sequencing data revealed P2Y14 ligands and P2Y14 receptor as a link between dying cells and HSCs, respectively. Treatment with P2Y14 ligands or coculture with dying hepatocytes promoted HSC activation in a P2Y14-dependent manner. P2Y14 ligands activated extracellular signal–regulated kinase (ERK) and Yes-associated protein (YAP) signaling in HSCs, resulting in ERK-dependent HSC activation. Global and HSC-selective P2Y14 deficiency attenuated liver fibrosis in multiple mouse models of liver injury. Functional expression of P2Y14 was confirmed in healthy and diseased human liver and human HSCs. In conclusion, P2Y14 ligands and their receptor constitute a profibrogenic DAMP pathway that directly links cell death to fibrogenesis.
- 6 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (639) , eabe5795
The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver
Fibrosis contributes to ~45% of deaths in western countries. In chronic liver disease, fibrosis is a major factor determining outcomes, but efficient antifibrotic therapies are lacking. Although platelet-derived growth factor and transforming growth factor–β constitute key fibrogenic mediators, they do not account for the well-established link between cell death and fibrosis in the liver. Here, we hypothesized that damage-associated molecular patterns (DAMPs) may link epithelial cell death to fibrogenesis in the injured liver. DAMP receptor screening identified purinergic receptor P2Y14 among several candidates as highly enriched in hepatic stellate cells (HSCs), the main fibrogenic cell type of the liver. Conversely, P2Y14 ligands uridine 5′-diphosphate (UDP)–glucose and UDP-galactose were enriched in hepatocytes and were released upon different modes of cell death. Accordingly, ligand-receptor interaction analysis that combined proteomic and single-cell RNA sequencing data revealed P2Y14 ligands and P2Y14 receptor as a link between dying cells and HSCs, respectively. Treatment with P2Y14 ligands or coculture with dying hepatocytes promoted HSC activation in a P2Y14-dependent manner. P2Y14 ligands activated extracellular signal–regulated kinase (ERK) and Yes-associated protein (YAP) signaling in HSCs, resulting in ERK-dependent HSC activation. Global and HSC-selective P2Y14 deficiency attenuated liver fibrosis in multiple mouse models of liver injury. Functional expression of P2Y14 was confirmed in healthy and diseased human liver and human HSCs. In conclusion, P2Y14 ligands and their receptor constitute a profibrogenic DAMP pathway that directly links cell death to fibrogenesis.
- Open Access
- 17 March 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 862330
Pulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis
Hepatic congestion occurs in patients with right heart failure and can ultimately lead to liver fibrosis or cardiac cirrhosis. Elevated pulmonary arterial pressure is found in patients with hepatic congestion. However, whether pulmonary arterial hypertension (PAH) can be a cause of liver fibrosis is unknown. The aim of this study was to investigate whether rats in the SuHx model with severe PAH develop liver fibrosis and to explore the mechanisms of congestive hepatic fibrosis both in rats and humans. To achieve this, PAH was induced in six to eight-week old male Sprague Dawley rats by a single subcutaneous injection of the VEGFR 2 inhibitor SU5416 and subsequent hypoxia for 3 weeks, followed by a 6-week period in room air. SuHx-exposed rats developed severe PAH, right ventricular hypertrophy (RVH), and consecutive right ventricular failure. Cardiac magnetic resonance imaging (MRI) and histological analysis revealed that PAH rats developed both hepatic congestion and liver fibrosis. Gene set enrichment analysis (GSEA) of whole liver RNA sequencing data identified a hepatic stellate cell specific gene signature in PAH rats. Consistently, tissue microarray from liver of patients with histological evidence of hepatic congestion and underlying heart disease revealed similar fibrogenic gene expression patterns and signaling pathways. In conclusion, severe PAH with concomitant right heart failure leads to hepatic congestion and liver fibrosis in the SU5416/hypoxia rat PAH model. Patients with PAH should therefore be screened for unrecognized liver fibrosis.
- 17 March 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 862330
Open AccessPulmonary Arterial Hypertension and Consecutive Right Heart Failure Lead to Liver Fibrosis
Hepatic congestion occurs in patients with right heart failure and can ultimately lead to liver fibrosis or cardiac cirrhosis. Elevated pulmonary arterial pressure is found in patients with hepatic congestion. However, whether pulmonary arterial hypertension (PAH) can be a cause of liver fibrosis is unknown. The aim of this study was to investigate whether rats in the SuHx model with severe PAH develop liver fibrosis and to explore the mechanisms of congestive hepatic fibrosis both in rats and humans. To achieve this, PAH was induced in six to eight-week old male Sprague Dawley rats by a single subcutaneous injection of the VEGFR 2 inhibitor SU5416 and subsequent hypoxia for 3 weeks, followed by a 6-week period in room air. SuHx-exposed rats developed severe PAH, right ventricular hypertrophy (RVH), and consecutive right ventricular failure. Cardiac magnetic resonance imaging (MRI) and histological analysis revealed that PAH rats developed both hepatic congestion and liver fibrosis. Gene set enrichment analysis (GSEA) of whole liver RNA sequencing data identified a hepatic stellate cell specific gene signature in PAH rats. Consistently, tissue microarray from liver of patients with histological evidence of hepatic congestion and underlying heart disease revealed similar fibrogenic gene expression patterns and signaling pathways. In conclusion, severe PAH with concomitant right heart failure leads to hepatic congestion and liver fibrosis in the SU5416/hypoxia rat PAH model. Patients with PAH should therefore be screened for unrecognized liver fibrosis.
- 1 March 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (3) , e6-e7
An Unusual Cause of Erythema on Both Lower Legs in a Patient With Crohn’s Disease
- 1 March 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (3) , e6-e7
An Unusual Cause of Erythema on Both Lower Legs in a Patient With Crohn’s Disease
- 1 August 2021
- Published by Georg Thieme Verlag KG
- Vol. 59 (08) , A 150
Pulmonalarterielle Hypertonie als Ursache von Leberfibrose im Rattenmodell
Einleitung Die pulmonalarterielle Hypertonie (PAH) ist eine Erkrankung der Lungenstrombahn, bei der ein erhöhter Blutdruck in den Lungenarterien zu einer Druckbelastung des rechten Ventrikels und in der Folge zu einer Rechtsherzinsuffizienz führt. Bekanntermaßen kann eine chronische Herzinsuffizienz zu einer Leberfibrose bis hin zur Cirrhose cardiaque führen. Ob PAH auch zu einer Leberfibrose führen kann, ist nicht ausreichend untersucht. Ziele Untersuchung von PAH im SU5416/Hypoxie-Ratten Modell im Hinblick auf die Entwicklung von Leberfibrose. Methodik 6-8 Wochen alte, männliche Sprague-Dawley Ratten wurden in drei Gruppen aufgeteilt: (A) Normoxie, (B) 3 Wochen Hypoxie (FiO2 0,1), gefolgt von 6 Wochen Raumluft (FiO2 0,21)], (C) einmalig s.c. VEGFR2 Inhibitor SU5416, 3 Wochen Hypoxie gefolgt von 6 Wochen Raumluft. Zum Versuchsende wurden bei den Tieren kardiale MRT, Echokardiographie (ECHO) und Herzkatheter durchgeführt, sowie die Leber für weitere Analysen entnommen. Ergebnis MRT, ECHO und Katheterdaten zeigten bei den Tieren der Gruppe C eine signifikante PAH Entwicklung im Vergleich zu Gruppe A und B. Als Zeichen venöser Kongestion zeigte sich eine Dilatation der Lebervenen im MRT sowie der Sinusoide in den H&E Färbungen. Tiere der PAH Gruppe (C) zeigten im Vergleich zu den Kontrollgruppen eine signifikante Zunahme der Leberfibrose gemessen mittels Picrosirius Red und Trichrome um 72 und 142 %. Analyse mittels qPCR konnte die Induktion fibrotischer Gene bestätigen. Gene Set Enrichment Analysis (GSEA) von RNA-Sequenzierung bzw. Nanostring zeigten sowohl bei Ratten mit PAH induzierter Leberfibrose als auch bei Patienten mit Leberfibrose bei chronischer Herzinsuffienz eine hepatische Sternzell-spezifische Gensignatur. Schlussfolgerung PAH führt zu einer Entwicklung von Leberfibrose im Rattenmodell. Patienten mit PAH sollten daher auch auf Zeichen von Leberfibrose untersucht werden. Publication Date: 07 September 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 August 2021
- Published by Georg Thieme Verlag KG
- Vol. 59 (08) , A 150
Pulmonalarterielle Hypertonie als Ursache von Leberfibrose im Rattenmodell
Einleitung Die pulmonalarterielle Hypertonie (PAH) ist eine Erkrankung der Lungenstrombahn, bei der ein erhöhter Blutdruck in den Lungenarterien zu einer Druckbelastung des rechten Ventrikels und in der Folge zu einer Rechtsherzinsuffizienz führt. Bekanntermaßen kann eine chronische Herzinsuffizienz zu einer Leberfibrose bis hin zur Cirrhose cardiaque führen. Ob PAH auch zu einer Leberfibrose führen kann, ist nicht ausreichend untersucht. Ziele Untersuchung von PAH im SU5416/Hypoxie-Ratten Modell im Hinblick auf die Entwicklung von Leberfibrose. Methodik 6-8 Wochen alte, männliche Sprague-Dawley Ratten wurden in drei Gruppen aufgeteilt: (A) Normoxie, (B) 3 Wochen Hypoxie (FiO2 0,1), gefolgt von 6 Wochen Raumluft (FiO2 0,21)], (C) einmalig s.c. VEGFR2 Inhibitor SU5416, 3 Wochen Hypoxie gefolgt von 6 Wochen Raumluft. Zum Versuchsende wurden bei den Tieren kardiale MRT, Echokardiographie (ECHO) und Herzkatheter durchgeführt, sowie die Leber für weitere Analysen entnommen. Ergebnis MRT, ECHO und Katheterdaten zeigten bei den Tieren der Gruppe C eine signifikante PAH Entwicklung im Vergleich zu Gruppe A und B. Als Zeichen venöser Kongestion zeigte sich eine Dilatation der Lebervenen im MRT sowie der Sinusoide in den H&E Färbungen. Tiere der PAH Gruppe (C) zeigten im Vergleich zu den Kontrollgruppen eine signifikante Zunahme der Leberfibrose gemessen mittels Picrosirius Red und Trichrome um 72 und 142 %. Analyse mittels qPCR konnte die Induktion fibrotischer Gene bestätigen. Gene Set Enrichment Analysis (GSEA) von RNA-Sequenzierung bzw. Nanostring zeigten sowohl bei Ratten mit PAH induzierter Leberfibrose als auch bei Patienten mit Leberfibrose bei chronischer Herzinsuffienz eine hepatische Sternzell-spezifische Gensignatur. Schlussfolgerung PAH führt zu einer Entwicklung von Leberfibrose im Rattenmodell. Patienten mit PAH sollten daher auch auf Zeichen von Leberfibrose untersucht werden. Publication Date: 07 September 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Top Cited Papers
- 1 June 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (11)
Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts
Cancer-associated fibroblasts (CAF) may exert tumor-promoting and tumor-suppressive functions, but the mechanisms underlying these opposing effects remain elusive. Here, we sought to understand these potentially opposing functions by interrogating functional relationships among CAF subtypes, their mediators, desmoplasia, and tumor growth in a wide range of tumor types metastasizing to the liver, the most common organ site for metastasis. Depletion of hepatic stellate cells (HSC), which represented the main source of CAF in mice and patients in our study, or depletion of all CAF decreased tumor growth and mortality in desmoplastic colorectal and pancreatic metastasis but not in nondesmoplastic metastatic tumors. Single-cell RNA-Seq in conjunction with CellPhoneDB ligand-receptor analysis, as well as studies in immune cell–depleted and HSC-selective knockout mice, uncovered direct CAF-tumor interactions as a tumor-promoting mechanism, mediated by myofibroblastic CAF–secreted (myCAF-secreted) hyaluronan and inflammatory CAF–secreted (iCAF-secreted) HGF. These effects were opposed by myCAF-expressed type I collagen, which suppressed tumor growth by mechanically restraining tumor spread, overriding its own stiffness-induced mechanosignals. In summary, mechanical restriction by type I collagen opposes the overall tumor-promoting effects of CAF, thus providing a mechanistic explanation for their dual functions in cancer. Therapeutic targeting of tumor-promoting CAF mediators while preserving type I collagen may convert CAF from tumor promoting to tumor restricting.
- 1 June 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (11)
Top Cited PapersTumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts
Cancer-associated fibroblasts (CAF) may exert tumor-promoting and tumor-suppressive functions, but the mechanisms underlying these opposing effects remain elusive. Here, we sought to understand these potentially opposing functions by interrogating functional relationships among CAF subtypes, their mediators, desmoplasia, and tumor growth in a wide range of tumor types metastasizing to the liver, the most common organ site for metastasis. Depletion of hepatic stellate cells (HSC), which represented the main source of CAF in mice and patients in our study, or depletion of all CAF decreased tumor growth and mortality in desmoplastic colorectal and pancreatic metastasis but not in nondesmoplastic metastatic tumors. Single-cell RNA-Seq in conjunction with CellPhoneDB ligand-receptor analysis, as well as studies in immune cell–depleted and HSC-selective knockout mice, uncovered direct CAF-tumor interactions as a tumor-promoting mechanism, mediated by myofibroblastic CAF–secreted (myCAF-secreted) hyaluronan and inflammatory CAF–secreted (iCAF-secreted) HGF. These effects were opposed by myCAF-expressed type I collagen, which suppressed tumor growth by mechanically restraining tumor spread, overriding its own stiffness-induced mechanosignals. In summary, mechanical restriction by type I collagen opposes the overall tumor-promoting effects of CAF, thus providing a mechanistic explanation for their dual functions in cancer. Therapeutic targeting of tumor-promoting CAF mediators while preserving type I collagen may convert CAF from tumor promoting to tumor restricting.
- 6 April 2021
- Published by Springer Nature in Die Innere Medizin
- Vol. 62 (5) , 570-571
Erratum zu: Massivste epigastrische Schmerzen bei einem 59-jährigen Patienten
- 6 April 2021
- Published by Springer Nature in Die Innere Medizin
- Vol. 62 (5) , 570-571
Erratum zu: Massivste epigastrische Schmerzen bei einem 59-jährigen Patienten